Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls
(2022) In American Journal of Transplantation 22(4). p.1245-1252- Abstract
Solid organ transplant recipients (SOTRs) are on lifelong immunosuppression, which may interfere with adaptive immunity to COVID-19. The data on dynamics and duration of antibody response in SOTRs are limited. This longitudinal study examined the longevity of both anti-spike (S)- and anti-nucleocapsid (N)-specific IgG antibodies after COVID-19 in SOTRs compared to matched immunocompetent persons. SOTRs (n = 65) were matched with controls (n = 65) for COVID-19 disease severity, age, and sex in order of priority. Serum-IgG antibodies against N and S antigens of SARS-CoV-2 were analyzed. At 1 and 9 months after COVID-19, anti-S-IgG detectability decreased from 91% to 82% in SOTRs versus 100% to 95% in controls, whereas the anti-N-IgG... (More)
Solid organ transplant recipients (SOTRs) are on lifelong immunosuppression, which may interfere with adaptive immunity to COVID-19. The data on dynamics and duration of antibody response in SOTRs are limited. This longitudinal study examined the longevity of both anti-spike (S)- and anti-nucleocapsid (N)-specific IgG antibodies after COVID-19 in SOTRs compared to matched immunocompetent persons. SOTRs (n = 65) were matched with controls (n = 65) for COVID-19 disease severity, age, and sex in order of priority. Serum-IgG antibodies against N and S antigens of SARS-CoV-2 were analyzed. At 1 and 9 months after COVID-19, anti-S-IgG detectability decreased from 91% to 82% in SOTRs versus 100% to 95% in controls, whereas the anti-N-IgG decreased from 63% to 29% in SOTRs versus 89% to 46% in controls. A matched paired analysis showed SOTRs having significantly lower levels of anti-N-IgG at all time points (1 month p =.007, 3 months p <.001, 6 months p =.019, and 9 months p =.021) but not anti-S-IgG at any time points. A mixed-model analysis confirmed these findings except for anti-S-IgG at 1 month (p =.005) and identified severity score as the most important predictor of antibody response. SOTRs mount comparable S-specific, but not N-specific, antibody responses to SARS-CoV-2 infection compared to immunocompetent controls.
(Less)
- author
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- antibody biology, clinical research/practice, immunosuppression/immune modulation, infection and infectious agents—viral, infectious disease, organ transplantation in general
- in
- American Journal of Transplantation
- volume
- 22
- issue
- 4
- pages
- 1245 - 1252
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85121146042
- pmid:34860447
- ISSN
- 1600-6135
- DOI
- 10.1111/ajt.16909
- language
- English
- LU publication?
- no
- id
- 0b90b2db-d72a-44ef-9895-b8cbaffa51fa
- date added to LUP
- 2022-01-31 15:16:13
- date last changed
- 2024-06-16 00:56:52
@article{0b90b2db-d72a-44ef-9895-b8cbaffa51fa, abstract = {{<p>Solid organ transplant recipients (SOTRs) are on lifelong immunosuppression, which may interfere with adaptive immunity to COVID-19. The data on dynamics and duration of antibody response in SOTRs are limited. This longitudinal study examined the longevity of both anti-spike (S)- and anti-nucleocapsid (N)-specific IgG antibodies after COVID-19 in SOTRs compared to matched immunocompetent persons. SOTRs (n = 65) were matched with controls (n = 65) for COVID-19 disease severity, age, and sex in order of priority. Serum-IgG antibodies against N and S antigens of SARS-CoV-2 were analyzed. At 1 and 9 months after COVID-19, anti-S-IgG detectability decreased from 91% to 82% in SOTRs versus 100% to 95% in controls, whereas the anti-N-IgG decreased from 63% to 29% in SOTRs versus 89% to 46% in controls. A matched paired analysis showed SOTRs having significantly lower levels of anti-N-IgG at all time points (1 month p =.007, 3 months p <.001, 6 months p =.019, and 9 months p =.021) but not anti-S-IgG at any time points. A mixed-model analysis confirmed these findings except for anti-S-IgG at 1 month (p =.005) and identified severity score as the most important predictor of antibody response. SOTRs mount comparable S-specific, but not N-specific, antibody responses to SARS-CoV-2 infection compared to immunocompetent controls.</p>}}, author = {{Søfteland, John M. and Gisslén, Magnus and Liljeqvist, Jan Åke and Friman, Vanda and de Coursey, Emily and Karason, Kristjan and Ekelund, Jan and Felldin, Marie and Magnusson, Jesper and Baid-Agrawal, Seema and Wallquist, Carin and Schult, Andreas and Jacobsson, Hanna and Bergdahl, Anders and Bemark, Mats and Andersson, Lars Magnus and Holm Gunnarsson, Inger and Stenström, Jan and Leach, Susannah}}, issn = {{1600-6135}}, keywords = {{antibody biology; clinical research/practice; immunosuppression/immune modulation; infection and infectious agents—viral; infectious disease; organ transplantation in general}}, language = {{eng}}, number = {{4}}, pages = {{1245--1252}}, publisher = {{Wiley-Blackwell}}, series = {{American Journal of Transplantation}}, title = {{Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls}}, url = {{http://dx.doi.org/10.1111/ajt.16909}}, doi = {{10.1111/ajt.16909}}, volume = {{22}}, year = {{2022}}, }